EMA CVMP 发布兽药使用者安全指南第2版草案(EMEA/CVMP/543/03-Rev.2)并征求意见
Draft guideline on user safety for pharmaceutical veterinary medicinal products - Revision 2
EMA 兽药委员会(CVMP)发布兽药使用者安全指南第2版草案(EMEA/CVMP/543/03-Rev.2)公开征求意见,评论截止2026年12月31日。草案替代 Rev.1,更新引用 Regulation (EU) 2019/6 及其附录II,并纳入 3Rs 与替代试验方法。
材料为兽药使用者安全指南第2版草案,列出风险评估流程章节与征求意见安排,可供读者定位需要核对的评估步骤。
PDF 文字版;图形和原始排版请参阅官方 PDF。
第 1 页
1 18 September 2026
2 EMEA/CVMP/543/03-Rev.2
3 Committee for medicinal products for veterinary use (CVMP)
4 Guideline on user safety for pharmaceutical veterinary
5 medicinal products
6 Draft
Draft agreed by Safety Working Party (SWP-V) 10 December 2025
Adopted by CVMP for release for consultation 10 September 2026
Start of public consultation 18 September 2026
End of consultation (deadline for comments) 31 December 2026
7
Comments should be provided using this template
8
Keywords User safety
9
10 This revision replaces the previous version of the CVMP guideline on user safety for pharmaceutical
11 veterinary medicinal products (EMEA/CVMP/543/03-Rev.1).
Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union
© European Medicines Agency, 2026. Reproduction is authorised provided the source is acknowledged.
第 2 页
12 Guideline on user safety for pharmaceutical veterinary
13 medicinal products
14 Table of contents
15 Executive summary ..................................................................................... 3
16 1. Introduction (background) ...................................................................... 3
17 2. Scope....................................................................................................... 3
18 3. Legal basis .............................................................................................. 4
19 4. Principles of the assessment ................................................................... 5
20 5. User risk assessment ............................................................................... 5
21 5.1. Hazard identification and characterisation................................................................ 5
22 5.1.1. Toxicity data on active substance(s) .................................................................... 6
23 5.1.2. Toxicity data on the formulation .......................................................................... 8
24 5.1.3. Conduct of toxicity studies .................................................................................. 8
25 5.2. Exposure assessment ........................................................................................... 9
26 5.2.1. Precise identification of the product, defining the properties of the veterinary
27 medicinal product ....................................................................................................... 9
28 5.2.2. Exposure scenarios ............................................................................................ 9
29 5.2.3. Characterisation of the population exposed, the type of user................................. 10
30 5.2.4. Defining the routes of exposure ......................................................................... 10
31 5.2.5. Defining the components of a product to which the user is exposed ....................... 10
32 5.2.6. Estimating the magnitude, duration and frequency of exposure ............................. 11
33 5.3. Risk characterisation ........................................................................................... 12
34 5.3.1. Qualitative risk characterisation......................................................................... 12
35 5.3.2. Quantitative risk characterisation ...................................................................... 12
36 5.4. Risk management .............................................................................................. 14
37 5.5. Risk communication ............................................................................................ 15
38 Definitions ................................................................................................. 17
39 References ................................................................................................ 20
40 Abbreviations ............................................................................................ 20
41 Annex 1 ..................................................................................................... 21
42 Example 1: URA based on a qualitative risk characterisation .......................................... 21
43 Example 2: URA based on a quantitative risk characterisation ........................................ 23
44 Annex 2 ..................................................................................................... 26
45 Template for a user risk assessment ........................................................................... 26
Guideline on user safety for pharmaceutical veterinary medicinal products
EMEA/CVMP/543/03-Rev.2 Page 2/26
第 3 页
46 Executive summary
47 The guideline on user safety for pharmaceutical veterinary medicinal products (VMPs) provides
48 guidance and advice on the procedure for user risk assessments. The guideline initially came into effect
49 in 2005 and was revised in 2010. The guideline has been further revised to reference current
50 legislation (i.e. Regulation (EU) 2019/6 and its Annex II), and to take into account updated definitions.
51 Opportunities for the implementation of the 3Rs (replacement, reduction, refinement) and alternative
52 testing approaches have also been included. This guideline has been updated to reflect the approaches
53 common to all pharmaceutical veterinary medicinal products. Additional guidance on the use of
54 uncertainty factors as they relate to the margin of exposure and consideration of the adequacy of risk
55 mitigation measures has also been included.
56 1. Introduction (background)
57 Marketing authorisations for veterinary medicinal products in the European Union are granted in
58 accordance with Regulation (EU) 2019/6. This legislation requires that applications for VMPs contain
59 safety documentation. Annex II of Regulation (EU) 2019/6 states that “the safety documentation shall
60 be adequate for assessment of (b) the potential risks which may result from the exposure of human
61 beings to the veterinary medicinal product, for example, during its administration to the animal.”
62 Furthermore, it provides that, with regard to user safety “This section shall include an assessment of
63 the effects found in Part II.3A to II.3A4 (or Part IIIa.3a to IIIa.3A4) and relate this to the type and
64 extent of human exposure to the product with a view to formulating appropriate user warnings and
65 other risk management measures.”
66 The legislation does not provide specific guidance on data requirements and assessment methods to be
67 used to identify the risks, or on the measures for risk reduction for users. This guideline presents
68 guidance and advice on user safety and the conduct of user risk assessments.
69 2. Scope
70 The objective of this guideline is:
71• to provide guidance and advice on user risk assessments.
72 While this guideline is primarily intended for pharmaceutical VMPs, it can also be applied to biologicals
73 other than immunologicals. For applications for immunological VMPs, guidance can be found in the
74 ‘Guideline on user safety for immunological veterinary medicinal products’
75 (EMA/CVMP/IWP/54533/2006 Rev.1).
76 The guideline applies to all Marketing Authorisation (MA) applications for pharmaceutical VMPs. This
77 also includes applications to vary the MA where there is an impact on user safety.
78 Some types of post-authorisation changes warrant a reassessment of user safety, for example:
79• Changes to the clinical use of the authorised products resulting in a significant increase in the handled
80 dose, including the duration of use;
81• The identification of new information impacting on the assessment of the risks of the VMP, such as new
82 hazard data on the ingredients of a product including new excipients;
83• A change of packaging material resulting in an increased potential for user exposure, especially taking
84 into account the volumes that may be spilled and the child-resistant properties.
85 For a generic product, a full user risk assessment would not normally be expected, as the conclusion
86 on user safety of the product and appropriate user safety warnings should reflect the user safety
Guideline on user safety for pharmaceutical veterinary medicinal products
EMEA/CVMP/543/03-Rev.2 Page 3/26
第 4 页
87 evaluation undertaken for the reference product. However, in accordance with Annex II of Regulation
88 (EU) 2019/6, section IV.1.2 (e), where there are aspects of the generic product that differ from the
89 reference product (e.g. composition in excipients), then the impact of these differences on user safety
90 should be addressed. For topical VMPs, for example, a difference (qualitative and quantitative) in
91 excipients may result in different exposure of the pet owner due to a possible change in dermal
92 absorption and/or the amount of VMP that is removed from the animal’s fur when stroked. In that
93 situation, the outcome of the risk assessment and subsequent risk mitigation measures may differ
94 from that of the reference product. This might also be the case when salts, esters, ethers, isomers and
95 mixtures of isomers, complexes or derivatives of the active substance of the reference VMP (i.e.
96 differences in the active substance) significantly affect safety, as referred to in Art 18(2) of Regulation
97 (EU) 2019/6. Also, where a difference in product packaging has been identified, the applicant must
98 justify why the risk to users remains unchanged for the generic product or implement appropriate risk
99 management measures (e.g., with respect to the need for a child-resistant closure).
100 The above is also applicable for hybrid products. In addition, in accordance with sections IV.2.2. and
101 IV.2.5 of Annex II of Regulation (EU) 2019/6, depending on the hybrid product, new data may be
102 required to support safety of the hybrid product.
103 In general, this guideline is not intended to be applied retrospectively (i.e. to products marketed prior
104 to the adoption of this guideline). However, according to article 58(4) of Regulation (EU) 2019/6 on the
105 responsibilities of the marketing authorisation holders, “The marketing authorisation holder shall
106 ensure that the summary of product characteristics, package leaflet and labelling is kept up to date
107 with current scientific knowledge.”
108 For applications for Marketing Authorisation for topical products, the guideline should be used in
109 conjunction with the ‘Guideline on user safety of topically administered veterinary medicinal products’
110 (EMA/CVMP/SWP/721059/2014).
111 For the assessment of user safety, the user is defined as any person that may come into contact with
112 the VMP or its components before its application to the animal (e.g. during storage), during its
113 application, and after its application (e.g. through contact with the treated animals).
114 The assessment of the user safety of a VMP should address the exposure situations resulting from the
115 normal conditions of use and from foreseeable accidents (including accidental ingestion by children and
116 accidental self-injection). It does not include exposure situations resulting from intentional misuse.
117 The guideline does not address occupational safety during the manufacture of veterinary medicinal
118 products but covers the incorporation of premixes (VMPs) into feed. Although Regulation (EU) 2019/6
119 does not apply to medicated feed, the user safety requirements are relevant to both the VMP and the
120 resulting medicated feed. Accordingly, this guideline may also be used to address the user safety
121 aspects of the medicated feed.
122 3. Legal basis
123 Requirements for safety testing for a marketing authorisation application are laid down in Regulation
124 (EU) 2019/6 of the European Parliament and of the Council.
125 This guideline concerns the application of the requirements of Annex II to Regulation (EU) 2019/6,
126 mentioned in Part 3 of Sections II for VMP other than biological VMP, and IIIa for biological VMP other
127 than immunological VMP, User safety shall “…include an assessment of the effects found in Part II.3A
128 to II.3.A4 (or Part IIIa.3a to IIIa.3A4) and relate this to the type and extent of human exposure to the
129 product with a view to formulating appropriate user warnings and other risk management measures.”
130 Moreover, “User safety shall be addressed in accordance with CVMP guidelines.”
Guideline on user safety for pharmaceutical veterinary medicinal products
EMEA/CVMP/543/03-Rev.2 Page 4/26
第 5 页
131 It should be noted that for an excipient used for the first time in a VMP or by a new route of
132 administration, the same data requirements as for the active substance should apply (see II.3A (3)
133 and IIIa.3A (3) of Regulation (EU) 2019/6).
134 All animal experiments should be conducted taking into account section I.1.7 of Annex II of Regulation
135 (EU) 2019/6 and the 3Rs principles (replacement, reduction and refinement), notwithstanding the
136 place of conduct of the experiments. Alternatives to in vivo test methods should be employed
137 whenever possible.
138 4. Principles of the assessment
139 A risk analysis presented for the VMP for users handling and administering it, or who become exposed
140 via contact with treated animals, should be provided and should address the following aspects:
141• Hazard identification and characterisation. An appraisal of the inherent toxicity of the VMP and
142 identification of the most relevant toxicological reference values (TRVs);
143• Exposure assessment. An appraisal of how and when the user may be exposed to the VMP –
144 identification of user groups, relevant exposure scenarios and estimation of the user exposure for each
145 scenario;
146• Risk characterisation. The assessment of the level of risk by establishing margins of exposure (MOEs)
147 through comparison of the exposure levels with the toxicological reference values, and the assessment
148 of local effects;
149• Risk management and communication. The proposal of appropriate and practical risk mitigation
150 measures, where relevant.
151 An appraisal of the inherent toxicity and any other harmful physico-chemical effects, such as
152 flammability, dustiness and volatility of the active substance and the formulation, should be conducted.
153 The hazards should be identified and characterised using appropriate data from toxicity tests or
154 published literature regarding relevant endpoints for local and systemic toxicity, taking into account
155 the route, duration, and frequency of anticipated exposure. The studies conducted should be relevant
156 to the route of exposure, for example, if only dermal exposure is anticipated, no information regarding
157 inhalation toxicity is deemed necessary.
158 An appraisal of the exposure of the user and any others who may come into contact with the VMP,
159 should be conducted. All possible exposure scenarios should be considered; these should include route
160 and level of exposure, frequency of use and amount used. The users, including all people possibly
161 exposed to the VMP, should be identified.
162 The procedure for the risk characterisation consists of comparing the exposure levels to which the user
163 is exposed or is likely to be exposed with those at which no adverse effects are expected to occur.
164 When there is a potential risk for the user, appropriate measures for risk reduction should be proposed
165 and evaluated.
166 5. User risk assessment
167 5.1. Hazard identification and characterisation
168 Generally, most of the toxicity data required to perform a hazard identification are already included in
169 the Marketing Authorisation dossier (Part IIIA Safety Documentation). The overall assessment of the
170 data allows a conclusion to be drawn on whether available data are sufficient for use in the risk
171 assessment. The potential need for additional studies depends on the exposure and any identified data
Guideline on user safety for pharmaceutical veterinary medicinal products
EMEA/CVMP/543/03-Rev.2 Page 5/26
第 6 页
172 gaps, and in some cases, the nature of the substances may indicate the need to focus on specific
173 endpoints of toxicity or pharmacology. The purpose is to derive toxicological reference values (TRV)
174 with respect to the identified exposure scenarios. If appropriate TRVs cannot be established for a
175 particular route of exposure or by route-to-route extrapolation, new studies should be performed to
176 generate route specific data. These new studies may be in vivo or based on scientifically valid
177 alternative methods, however, a stepwise approach should be employed, with animal testing used only
178 where absolutely necessary. The results of all provided studies should be assessed in order to identify
179 the potential adverse health effects that can be caused by exposure to the substance(s) of concern.
180 This applies to the active substance(s) as well as new excipients, and may also apply to other
181 excipients which cause concern (e.g. an excipient which is known to be harmful).
182 5.1.1. Toxicity data on active substance(s)
183 The toxicity data presented in the dossier relating to the active substance may be derived from animal
184 or non-animal toxicity studies or from published literature. These studies should ideally be designed
185 and selected to investigate the effects of single doses and repeated doses, and to consider endpoints
186 for effects on reproductive performance, fertility, developmental toxicity, genotoxicity and
187 carcinogenicity. In line with the 3Rs, it is recommended to derive information on single dose toxicity
188 from existing studies, e.g. from repeated dose or developmental toxicity studies. Depending on the
189 type of product, special studies may have been conducted, for example to investigate inhalation
190 toxicity, sensitisation potential, skin and eye irritation, or immunotoxicity or neurotoxicity.
191 Whenever possible, dose-response relationships should be identified in order to derive a TRV, i.e. the
192 no observed adverse effect level (NOAEL), or, if this is not possible, the lowest observed adverse effect
193 level (LOAEL). The use of the benchmark dose lower confidence limit (BMDL) is also acceptable as a
194 point of departure. Using the BMDL as a point of departure has the advantage that it provides a
195 quantitative dose-response assessment taking into account the variability of the data and the slope of
196 the dose-response curve.
197 It is considered that the use of LD50 values as TRVs is not appropriate, as at this dose adverse effects
198 already occur. Furthermore, LD50 studies generally provide only limited toxicological information and
199 are therefore, not suitable for deriving NO(A)ELs.
200 Target animal safety studies should normally not be used for the derivation of TRVs as they are not
201 designed for this purpose, but for observing adverse effects at the therapeutic dose (and overdoses) in
202 the target animal. However, these studies may in exceptional cases contain the most sensitive
203 endpoint and might then be employed for the derivation of TRVs. Similarly, pharmacovigilance data
204 can provide additional information for a substance or product, though they cannot be used to define a
205 NO(A)EL.
206 TRVs are established for all relevant toxicological endpoints (critical effects), and are specific to a
207 substance, duration of exposure (acute, sub-chronic or chronic) and route of exposure (oral, dermal
208 and inhalation). Pharmacological effects should also be considered, i.e. when the dose associated with
209 pharmacological effect is below the toxicological TRV. The appropriate TRV for quantitative risk
210 assessment is to be selected considering the route of user exposure, the duration of user exposure and
211 the substance concerned. If more than one NOAEL is available for a given exposure scenario, the
212 choice of the NOAEL to be used as the TRV should be fully justified.
213 In the context of a risk assessment, these TRVs should be compared to exposure levels of the
214 substance(s) of concern that correspond to similar durations and routes of exposure. In the absence of
215 a TRV for a specific route of exposure (e.g. dermal), the use of a TRV defined from an oral study
216 should be considered using route-to-route extrapolation with appropriate adjustments to address
Guideline on user safety for pharmaceutical veterinary medicinal products
EMEA/CVMP/543/03-Rev.2 Page 6/26
第 7 页
217 differences in bioavailability. Further information on route-to-route extrapolation can be found in the
218 ‘Guideline on user safety of topically administered veterinary medicinal products’
219 (EMA/CVMP/SWP/721059/2014). Even if the TRV is based on the most sensitive critical effect, other
220 effects may also be taken into consideration (e.g. reproductive or developmental effects) in order to
221 focus the user safety risk assessment on specific scenarios or user groups. For instance, any possible
222 adverse effect on the pregnant female and the development of the embryo and foetus, or on male and
223 female fertility, should be assessed using an appropriate TRV.
224 In the case of developmental toxicity, Annex II to Regulation (EU) 2019/6 states that ‘For the
225 evaluation of user safety, standard developmental toxicity testing in accordance with standard tests
226 based on established guidance (including VICH GL32 and OECD tests) shall be performed in all cases
227 where significant user exposure may be expected.’ In this context, significant user exposure is
228 considered to occur where systemic exposure to the substance is possible. Significant exposure is not
229 expected to occur where it can be demonstrated that absorption following oral ingestion or from sites
230 of local exposure (e.g. skin or eyes) will lead to negligible systemic exposure (e.g. substances that are
231 not absorbed). In addition to the absorption properties of the substance, characteristics of the product
232 formulation can result in negligible exposure (e.g. coated or non-divisible tablets, as it is expected that
233 these forms leave minimal to no residues on the skin). Where standard developmental toxicity tests
234 are not provided, based on a claim of negligible exposure, adequate justification and supporting data
235 for the omission of such studies should be provided.
236 Where systemic exposure cannot be avoided following exposure to the veterinary medicinal product,
237 significant exposure is assumed. In that case, the risk to the pregnant user should be assessed. In
238 order to avoid unnecessary animal testing this should be done by employing first, all existing
239 information on developmental toxicity in a weight of evidence approach that supports a quantitative
240 risk assessment, i.e. allows for the derivation of a safe dose for the user. Such information can include,
241 for example, studies from published literature, data derived from in vitro methods, observations in
242 humans, etc. If no adequate conclusion on a safe dose or a mitigable risk for pregnant women can be
243 drawn based on available information, standard developmental toxicity tests should be conducted.
244 If the active substance has been used in human medicines, then any available data, including company
245 data as well as data in the published literature, relating to observations and adverse reactions in
246 humans should be submitted in the dossier. If generated experimentally in humans, the applicant
247 should confirm that the studies were conducted in accordance with recognised ethical standards 1.
248 Available human data can also be considered for the derivation of TRVs if these studies are relevant
249 from a scientific point of view and can be employed for quantitative risk assessment. However, for any
250 given substance, the accepted therapeutic dose used in human medicine does not imply an absence of
251 risk and, therefore, is generally not acceptable as a TRV.
252 In the case of 'fixed combination products', containing two or more active substances, data on
253 individual active substances should be considered as the basis. However, it may also be necessary to
254 provide toxicological data for the combination if there are interactions between the active substances
255 such as synergistic effects, in accordance with the EMA ‘Guideline on pharmaceutical fixed combination
256 products’ (EMA/CVMP/83804/2005).
257 Studies reported in the scientific literature may be accepted if they contain a sufficient amount of data
258 and sufficient details to allow an independent assessment by the competent authority (see also section
259 II.3(2) of Regulation (EU) 2019/6). Information from EPMARs can be summarised; in that case there is
1 If data are provided from studies conducted in humans it should be confirmed that the study was conducted in
accordance with the ethical principles that have their origins in the Declaration of Helsinki.
Guideline on user safety for pharmaceutical veterinary medicinal products
EMEA/CVMP/543/03-Rev.2 Page 7/26
第 8 页
260 no need to submit studies already evaluated as part of the MRL evaluation, only new studies should be
261 provided.
262 5.1.2. Toxicity data on the formulation
263 The systemic effects are usually assessed only for the active substance(s). However, when there is a
264 specific concern with regard to systemic effects due to the presence of one or more of the excipients in
265 the VMP (e.g. an excipient which is known to be harmful), it may be necessary to assess the systemic
266 toxicity of these excipients or of the formulated product.
267 For toxicity studies on local effects, Annex II to Regulation (EU) 2019/6 states that “For products for
268 which there may be exposure to skin and eyes, irritation and sensitisation studies shall be provided.”
269 In the case of pharmaceutical VMPs (Section II.3A.4.1), “those studies should be conducted with the
270 final formulation”, whereas for biological VMPs other than immunological VMPs (Section III.3A.4.1),
271 “those studies should usually be conducted with the final formulation.” New data should be generated
272 using in vitro methods as described in current OECD test guidelines (see 5.1.3.), e.g. skin
273 irritation/corrosion test methods in OECD Test Guidelines 430, 431, 435, 439; eye irritation/corrosion
274 test methods in OECD Test Guidelines 437, 438, 460, 467, 491, 492, 492B, 494, 496; and skin
275 sensitisation OECD Test Guidelines 442C, 442D, 442E, 497. However, many of these test methods
276 have not been validated for mixtures. In that case, it would be acceptable to test the single substances
277 of the VMP using these in vitro methods instead of the final product formulation. Nonetheless, full
278 consideration should be given to possible interaction between active substances and/or excipients.
279 Additionally, in the interest of reducing testing requirements in animals, if there are only historical data
280 or published literature on the ingredients of the formulation, the potential effects of a VMP can be
281 deduced from these data. If the test article is irritating to the skin, it is assumed that it is also irritating
282 to the eyes.
283 5.1.3. Conduct of toxicity studies
284 If toxicity tests are conducted to address any identified gaps in the dataset, they should be carried out
285 in accordance with VICH/OECD guidance and current methodology and, where advised, should follow a
286 stepwise approach (e.g. studies to evaluate genotoxicity (VICH GL23)). Validated 2 or qualified 3
287 alternative test methods should be employed whenever possible. Information on opportunities for
288 limiting animal use in current testing requirements is provided in the “Reflection paper on providing an
289 overview of the current regulatory testing requirements for veterinary medicinal products and
290 opportunities for implementation of the 3Rs” (EMA/CHMP/CVMP/3Rs/164002/2016). This document is
291 updated regularly and the most recent version should be consulted for reference.
292 It is noted that for some endpoints, standardised test methods are currently not available, in particular
293 for parenteral toxicity (e.g. from injectable VMPs) and respiratory sensitisation. However, for
294 parenteral toxicity, target animal safety studies may provide relevant information on local and
295 systemic effects following this route of exposure. Data on skin sensitisation may serve as a surrogate
296 for respiratory sensitisation, in the absence of appropriate methods.
2 Validated according to OECD guidance document 34 (https://www.oecd.org/en/publications/guidance-document-on-the-
validation-and-international-acceptance-of-new-or-updated-test-methods-for-hazard-assessment_e1f1244b-en.html)
3 Qualified according to EMA guideline EMA/CHMP/CVMP/JEG-3Rs/450091/2012
(https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-principles-regulatory-acceptance-3rs-
replacement-reduction-refinement-testing-approaches_en.pdf)
Guideline on user safety for pharmaceutical veterinary medicinal products
EMEA/CVMP/543/03-Rev.2 Page 8/26
第 9 页
297 5.2. Exposure assessment
298 Exposure is the contact between an agent and a target, i.e. of a VMP with a user. Exposure assessment
299 is the process that involves estimating the magnitude, frequency, and duration of exposure to a VMP
300 for a specific substance, route of exposure and user.
301 The process includes:
302• Precise identification of the product, defining the properties of the VMP (5.2.1)
303• Exposure scenarios (5.2.2)
304• Characterisation of the population exposed, including the type of user (5.2.3)
305• Defining the routes of exposure (5.2.4)
306• Defining the components of the product to which the user is exposed (5.2.5)
307• Estimating the magnitude, duration and frequency of exposure (5.2.6)
308 The elements are further discussed below.
309 5.2.1. Precise identification of the product, defining the properties of the
310 veterinary medicinal product
311 The first step in the exposure assessment is to consider the properties of the VMP. This should cover
312 the following items:
313• the pharmaceutical form
314• relevant physico-chemical properties
315• the presentation (quantity available to the user, packaging)
316• the method of use, including the route of administration and any dosing equipment to be used
317 5.2.2. Exposure scenarios
318 The next step in the exposure assessment is to identify the exposure scenarios, starting with tasks
319 and/or situations that may lead to exposure of humans. Different phases before, during and after
320 administration of the product to the animal(s) should be considered.
321 Table 1 illustrates different tasks and situations that may be relevant for a VMP. It should be noted
322 that these are examples only and that there are other situations that may be considered depending on
323 the VMP.
324 Table 1. Some examples of tasks and situations that may lead to exposure
Pre-administration phase Administration phase Post-administration phase
Storage Opening or accessing the Cleaning equipment &
product: e.g., taking product preparation areas
out of packaging Disposal activities: e.g.,
Mixing and/or diluting of disposal of packaging,
concentrates: e.g., mixing with equipment & surplus product
feed & water Handling treated animals
Loading application apparatus including stroking
or system: e.g., dosing gun
Guideline on user safety for pharmaceutical veterinary medicinal products
EMEA/CVMP/543/03-Rev.2 Page 9/26
第 10 页
Administration to the animal(s):
e.g., holding/restraining animal
for treatment
325 For products containing particularly hazardous substances (e.g. DNA reactive/cytotoxic products),
326 post-administration exposure to excreta (e.g. vomit, saliva) should also be considered (see the
327 Guideline on dossier requirements for anticancer medicinal products for dogs and cats
328 (EMA/CVMP/28510/2008) for further guidance).
329 Once the tasks and situations that lead to exposure are identified, the exposure for each task/situation
330 should be further characterised. See the subsections below.
331 5.2.3. Characterisation of the population exposed, the type of user
332 It is important to clearly identify the different types of users of the product and to include all users that
333 might come into contact with the VMP, some of whom may not necessarily be administering the VMP,
334 but may be indirectly exposed to the VMP.
335 Some examples of people who are users are: a veterinarian, a veterinarian’s assistant, a farmer, a
336 bystander, a breeder, a pet-owner, a person living in the same building (e.g. child), a canine
337 beautician or a sheep shearer. With regard to medicated premixes, the user of the VMP will be the
338 individual incorporating the premix into a medicated feed or intermediate product. In addition,
339 although Regulation (EU) 2019/6 does not apply to medicated feed, it is recommended that the
340 exposure scenario for the end-user, i.e. the handler of the medicated feed, including young children
341 who may have access to the medicated feed, be considered when assessing user safety.
342 When a VMP is kept in the home or in places where children may be present (e.g. horse stables),
343 children should be identified as users.
344 5.2.4. Defining the routes of exposure
345 The routes of exposure should be specified for each exposure scenario. The routes of exposure will
346 generally depend on the type of product, the pharmaceutical form, and the dosing equipment (if any).
347 The routes to be considered are dermal, inhalation, ocular, and parenteral (accidental self-injection),
348 with oral exposure often assessed.
349 Oral exposure should be considered for children. The inclusion of the warning “keep out of the sight
350 and reach of children” on the label and package leaflet of products is a standard phrase for all VMPs,
351 regardless of whether a risk is identified or not. However, the risks of oral ingestion should always be
352 considered for products for which children have been identified as users (see section 5.3.2). If the
353 toxicity data and subsequent risk characterisation suggest that there may be a concern after accidental
354 ingestion, minimising exposure to children should be addressed. This might be achieved by inclusion of
355 specific user safety warnings with respect to the storage of a VMP (e.g. storage of unused tablet parts
356 in the blister or not to leave a filled syringe unattended), or by considering child-resistant packaging.
357 For adult users, oral exposure due to hand-to-mouth contact should be considered when dermal
358 exposure is likely due to handling the product or from stroking a pet when there are residues on the
359 fur. The non-respirable fraction of an inhalation exposure is also considered to be swallowed.
360 5.2.5. Defining the components of a product to which the user is exposed
361 Users can be exposed to:
Guideline on user safety for pharmaceutical veterinary medicinal products
EMEA/CVMP/543/03-Rev.2 Page 10/26
第 11 页
362• the whole product (e.g. a powder, a concentrate), including its active and inactive ingredients;
363• certain components of the product (e.g. an active substance released from a collar);
364• solutions or dilutions of a product (e.g. medicated drinking water; spray mists from dosing equipment).
365 For each exposure scenario, it should be specified to what (e.g. whole product, components, dilution)
366 the user is exposed.
367 5.2.6. Estimating the magnitude, duration and frequency of exposure
368 Information on the magnitude, duration and frequency of exposure is needed in order to estimate the
369 user exposure level to be used in the quantitative risk characterisation.
370 Although all situations that lead to exposure can be considered, it will not mean that each of these
371 situations will occur every time the product is used. For example, “accidental self-injection” is an
372 exposure situation, but there is a low probability that this event will actually happen when the product
373 is used, i.e. it is a rare event and has a very low frequency. However, when applying a medicated
374 shampoo to a dog, skin contact with the shampoo during application will occur almost every time it is
375 used; dermal exposure is therefore considered to have a high frequency. Dermal and hand-to-mouth
376 exposure from coated or non-divisible tablets is generally considered to be negligible.
377 The magnitude, duration and frequency of exposure determine the quantitative part of an exposure
378 scenario.
379 The exposure level should be estimated by the applicant on the basis of experience with the product or
380 comparable types of products, taking into account the use of the product by all users, and the pattern
381 of use (single use or repeated (consecutive or interval) administration).
382 The magnitude of exposure is often determined by parameters like the dose or volume handled,
383 concentration (e.g. in solutions or in air), release rate (e.g. from a collar or from a spray apparatus),
384 vapour pressure, particle size, droplet size and spray pattern; from these data the external dose for a
385 user is estimated.
386 To estimate the internal dose, the pharmacokinetic properties (in particular data on absorption and
387 bioavailability) of the relevant compounds should be taken into account.
388 The estimation of the exposure levels may include measured data as well as model calculations. Any
389 assumptions made in the exposure assessment should be clearly indicated and justification should be
390 given, and the input data or default values used for the calculations should be documented.
391 When considering the exposure level per kg of bodyweight, a default bodyweight of 60 kg is used by
392 CVMP for adults. For children, the default bodyweight is 12.5 kg, considered to represent a child aged
393 2 to <3 years old who is active in exploring their environment. This value is derived from a study in
394 the Dutch population (considered to be representative for the European population) and corresponds to
395 the 25th percentile of the Dutch population; 12.4 kg (RIVM report 090013003/2014), rounded up to
396 12.5 kg.
397 Examples of exposure parameters that can influence the magnitude of exposure, include surface areas
398 of body parts, respiratory rates, size and volume of a room, dip tank volume, and ventilation rates of
399 rooms.
400 Irrespective of the method used, the prediction of the exposure levels should describe a reasonably
401 worst-case situation.
Guideline on user safety for pharmaceutical veterinary medicinal products
EMEA/CVMP/543/03-Rev.2 Page 11/26
第 12 页
402 If more than one route of exposure is involved in a single situation (e.g. dermal and oral exposure due
403 to hand-to-mouth contact), the total systemic exposure (sum of routes) should be calculated. In some
404 cases, the same compound or product is to be used to treat an animal and its environment (e.g. a flea
405 powder). When it is foreseeable that animal beddings, premises etc. will be treated as well, an
406 assessment of aggregate exposure from both uses should be made. Similarly, if several animals are to
407 be treated at the same time (e.g. a flock of sheep), the estimation of the exposure level should be
408 made for multiple applications.
409 5.3. Risk characterisation
410 5.3.1. Qualitative risk characterisation
411 For a number of toxicological endpoints, the methods for testing provide qualitative results. This is in
412 particular the case for certain local effects, for example, sensitisation or irritation. For these effects, no
413 information on dose-response relationships will be available and, hence, thresholds remain unknown.
414 Consequently, no quantitative risk assessment can be made for the anticipated exposure levels.
415 Instead, only a hazard identification can be made.
416 Although a quantitative risk characterisation cannot be made for these endpoints, the risk may be
417 qualitatively characterised, taking into account the likelihood that such an effect will occur on the basis
418 of the concentration in the VMP and/or exposure information. Whenever possible, available information
419 on the severity of an effect at the anticipated exposure levels should be taken into account as well. If
420 such information is not available, it should be assumed that the effects will occur at any exposure
421 level.
422 In addition, risks to the user related to the physico-chemical properties should be identified, such as
423 pH and flammability.
424 An example to illustrate this procedure is given in Annex 1 (example 1).
425 5.3.2. Quantitative risk characterisation
426 The procedure for the quantitative risk assessment consists of comparing the exposure levels to which
427 the user is exposed or is likely to be exposed with the exposure levels at which no adverse effects are
428 expected to occur. This is generally done by comparing the estimated exposure to the relevant TRV,
429 i.e. calculating the margin of exposure (MOE).
430 The duration of the study from which the TRV is derived should preferably reflect the duration of
431 exposure of the user. The risk assessment of short-term exposure should be based on acute TRVs or, if
432 not available, on sub-acute or sub-chronic TRVs, the latter representing, in general, a worst-case
433 approach. In light of the 3Rs, specific acute studies should not be performed to derive an acute TRV.
434 Instead, the acute TRV should be derived from acute effects observed in other study types, e.g. sub-
435 chronic or developmental toxicity studies. For the risk assessment of long-term exposure, the use of a
436 sub-chronic or chronic TRV can be considered acceptable, depending on the longest duration of user
437 exposure, including exposure due to repeated treatment of the animal.
438 When comparing the estimated exposure to the relevant TRV, the following parameters should be
439 considered:
440• the intra- and interspecies variation 4;
4
To account for uncertainty related to interspecies variation (i.e. extrapolation from animals to humans) a standard factor of x10 is
used unless there is reliable data to deviate from this.
Guideline on user safety for pharmaceutical veterinary medicinal products
EMEA/CVMP/543/03-Rev.2 Page 12/26
第 13 页
441• the nature and severity of the effect;
442• the human population to which the exposure information applies;
443• the differences in exposure (route, duration, frequency);
444• the dose-response relationship observed;
445• the overall confidence in the available data.
446 These parameters are used to establish an uncertainty factor, which the MOE will then be compared to.
447 It is generally recognised that the default uncertainty factor (UF) is 100, i.e. an MOE of 100 or higher
448 would be considered acceptable. This value of 100 is the product of two factors of 10, one for
449 interspecies extrapolation and the other for intraspecies (inter-individual) variability. The interspecies
450 uncertainty factor is used for extrapolating the animal derived TRV to an average healthy individual,
451 taking into account that humans may be more sensitive than laboratory animals. The intraspecies
452 factor takes into account susceptible human subpopulations.
453 Where reliable data are available, there may be a case for accepting an MOE other than 100, e.g. if
454 there is a case for accepting that the standard values for inter- and intraspecies variation do not apply.
455 Similarly, the nature of the studies used to determine a TRV will also influence the uncertainty factor.
456 For example, if the TRV is based on a NO(A)EL derived from a human study, then an MOE of 10 could
457 be accepted as no interspecies extrapolation is required. Note that the accepted therapeutic dose used
458 in human medicine does not imply an absence of risk and, therefore, it is generally not acceptable as a
459 TRV.
460 The nature and severity of observed effects also influence risk assessments based on a NO(A)EL. The
461 magnitude of the uncertainty factor can be increased for effects such as non-genotoxic carcinogenicity,
462 neurotoxicity or teratogenicity. Severe adverse effects such as these may require an additional factor
463 of between 2 and 10 and may also be applied only to a specific human population, e.g. pregnant
464 women. For example, the observation of teratogenic effects would warrant an additional uncertainty
465 factor of 5 – 10. If the TRV is a lowest observed (adverse) effect level (LO(A)EL) then an additional
466 factor of 2 - 5 would be required, depending on the dose-response relationship and/or the severity of
467 effects observed.
468 While from a scientific point of view the exposure route of the study from which the TRV is derived
469 should preferably reflect the route of exposure of the user, from a 3Rs point of view the use of existing
470 data is encouraged. To this end, route-to-route extrapolation would need to be employed (see also the
471 Guideline on user safety of topically administered VMPs for more detailed information on route-to-route
472 extrapolation). Also, a difference in duration of the study may be a case for accepting an MOE either
473 higher or lower than 100. With respect to the overall confidence in the available data, it should be
474 noted that, in order to compensate for deficiencies in toxicity data, an additional factor may be
475 required, increasing the acceptable MOE above the default factor of 100.
476 Where appropriate and justified, available toxicological limit values or exposure limit values (e.g. AOEL
477 or other occupational limits, ARfD, ADI) may be used as alternatives to the MOE approach as described
478 above. For some derived reference values (e.g. ADI and ARfD) the level of uncertainty has already
479 been taken into account in its calculation. If sufficient uncertainty factors were applied and the same
480 type of exposure is being assessed, exposure can be directly compared to this reference value. For
To account for uncertainty related to intraspecies variation (i.e. differences in human susceptibility) a standard factor of x10 is used
unless there is reliable data to deviate from this.
When alternative factors are proposed, consideration must be given to the guidance document published by the IPCS/WHO
(IPCS/WHO, 2005).
Guideline on user safety for pharmaceutical veterinary medicinal products
EMEA/CVMP/543/03-Rev.2 Page 13/26
第 14 页
481 example, if the estimated oral exposure is less than the ADI, the risk for the user is considered to be
482 acceptable.
483 With multiple factors influencing the magnitude of the acceptable MOE, adequate justification for each
484 parameter should be provided. The acceptability of the MOE and, thus, the risk to the user will require
485 expert judgement. In the case of a potential risk to the user, risk management options should be
486 proposed and evaluated.
487 An example to illustrate this procedure is given in Annex 1 (example 2).
488 5.4. Risk management
489 Users
490 Some users will have more experience and knowledge of handling and administering VMP to animals
491 than others, such as veterinarians or farmers, and this needs to be acknowledged in the assessment.
492 Similarly, when considering other users who do not administer VMP on a frequent basis, such as pet
493 owners, more detailed risk mitigation measures may be required in order to handle and administer the
494 product safely.
495 Some users may have limited access to personal protective equipment (PPE) and, therefore, if
496 required, there must be advice on what PPE is needed or the PPE has to be provided with the VMP.
497 In the case of users incorporating premixes into feed and users of the medicated feed, consideration
498 should be given to the need for separate advice and warnings for the different types of users (e.g. PPE
499 may be required when incorporating the premix, but not when administering the medicated feed).
500 Risk control options
501 In general, the following options for risk control may be used:
502• restriction of the distribution, for example, as prescription-only medicine;
503• specific warnings for groups at risk, for example, sensitised people, pregnant women, or where there
504 are risks to fertility;
505• restriction of application methods, for example, pour-on instead of spraying or the use of closed
506 delivery systems;
507• restriction of the field of use, for example, outdoor use only;
508• modification of the formulation, for example, ready-to-use rather than a concentrate;
509• modification of packaging, for example, reduced pack size or child-resistant packaging*;
510• recommendation of measures for the protection of users, for example, general controls like ventilation
511 of rooms, or use of PPE like protective gloves, masks or goggles. The appropriateness, i.e. the inherent
512 efficiency, of these measures should be discussed. For example, the choice of materials should be
513 justified (it is well known that certain substances are able to permeate or penetrate through certain
514 materials, e.g. solvents through latex gloves).
515 *Note: Packaging can be claimed as child-resistant packaging only if it has been demonstrated to be
516 child-resistant in accordance with the European Standard EN14375 for non-reclosable packaging or
517 EN8317 for reclosable packaging.
518 The proposed risk control measures should be evaluated against the following criteria:
Guideline on user safety for pharmaceutical veterinary medicinal products
EMEA/CVMP/543/03-Rev.2 Page 14/26
第 15 页
519• the extent to which the exposure is reduced by a risk control measure, alone or in combination with
520 other measures, must be large enough to reduce the risk to an acceptable level;
521• the measure should be practicable, for example, PPE must be readily available to the user, and
522 measures should not hamper the use of the product too much. It is considered unreasonable, for
523 example, to expect a pet-owner to have access to personal protective equipment beyond normal
524 household gloves. Therefore, in exceptional cases, it might be appropriate to provide adequate PPE
525 with the VMP.
526 5.5. Risk communication
527 The warnings and safety measures are communicated via the SPC and package leaflet and should
528 inform the user about the following aspects:
529A. The concerned risk, i.e. the identified hazard
530B. What exposure must be avoided to minimise the concerned risk
531C. How to avoid that exposure
532D. What to do in the event of exposure (if relevant)
533 The following illustrations explain this:
534 Example 1: A liquid product that is administered by the farmer using a spray gun to a flock of sheep,
535 is irritant to the eyes. The warnings in the SPC and on the package leaflet would be:
536 • This veterinary medicinal product can cause eye irritation. (A)
537 • Avoid contact with the eyes including hand-to-eye contact. (B)
538 • Personal protective equipment consisting of protective glasses should be worn when handling the
539 veterinary medicinal product. (C)
540 • Wash hands after use. (D)
541 • When the veterinary medicinal product comes into contact with the eyes, rinse immediately with
542 plenty of water. In case irritation persists, seek medical advice immediately and show the package
543 leaflet or the label to the physician. (D)
544 In the A-phrase it is recommended to specify the actual hazard, i.e. in this situation this VMP can
545 cause eye irritation. Other examples could be ‘This veterinary medicinal product can cause sedation.’
546 or ‘This veterinary medicinal product can cause neurotoxicity.’, etc.
547 Example 2: An antibiotic tablet containing a penicillin, that is administered by the pet owner to dogs,
548 and for which hypersensitivity reactions may be expected. The warnings in the SPC and on the
549 package leaflet would be:
550 • <This veterinary medicinal product> <Penicillins and cephalosporins> may cause hypersensitivity
551 (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins
552 may lead to cross-reactions to cephalosporins and vice versa. Allergic reactions to these
553 substances may occasionally be serious. (A)
554 • People with known hypersensitivity to penicillins or cephalosporins should avoid contact with the
555 veterinary medicinal product. (B)
556 • Handle this veterinary medicinal product with great care to avoid exposure. (C)
557 • Wash hands after use. (D)
Guideline on user safety for pharmaceutical veterinary medicinal products
EMEA/CVMP/543/03-Rev.2 Page 15/26
第 16 页
558 • If you develop symptoms following exposure, such as a skin rash, you should seek medical advice
559 and show the package leaflet or the label to the physician. Swelling of the face, lips or eyes or
560 difficulty in breathing are more serious symptoms and require urgent medical attention. (D)
561 The substance(s) that might cause hypersensitivity reactions should always be specified.
562 Example 3: An injectable that is administered by a professional user, and is assessed to be
563 teratogenic, embryo- or foetotoxic. The warnings in the SPC and on the package leaflet would be:
564 • This veterinary medicinal product may be harmful to the unborn child. (A)
565 • Avoid contact with the skin and accidental self-injection. (B)
566 • Pregnant women, or women trying to conceive, should administer the veterinary medicinal product
567 with serious caution to avoid accidental self-injection. (C)
568 • Personal protective equipment consisting of impervious gloves should be worn when handling the
569 veterinary medicinal product. (C)
570 • In case of accidental skin exposure, wash hands/exposed skin thoroughly. In case of accidental
571 self-injection, seek medical advice immediately and show the package leaflet or the label to the
572 physician. (D)
573 Note that different risk mitigation measures might be applicable for professional or non-professional
574 users administering the same substance, depending on the formulation of the VMP, the risk
575 characterisation, and also on the level of experience of the user.
576 The user safety warnings should be written and designed to be readable, clear and understandable, in
577 terms that are comprehensible to the general public. The user safety warnings should be justified. User
578 safety warnings should be written in full in the SPC and the package leaflet. In general, the label only
579 contains the information ‘Read the package leaflet before use’.
580 For additional guidance on the presentation of user safety warnings in the product information, the
581 reader is referred to the most recent version of the Quality Review of Documents veterinary product
582 information template.
583 Two worked examples of User Risk Assessments (URAs) are presented in Annex I of this guideline to
584 show a qualitative risk characterisation and a quantitative risk characterisation. Furthermore, a
585 template for a URA is provided in Annex II.
586
Guideline on user safety for pharmaceutical veterinary medicinal products
EMEA/CVMP/543/03-Rev.2 Page 16/26
第 17 页
587 Definitions
Acceptable daily intake (ADI) The estimate of the amount of a substance, expressed in terms of
micrograms or milligrams per kilogram of bodyweight, that can be
ingested daily over a lifetime without posing any appreciable health
risk.
Acute reference dose (ARfD) An estimate of the exposure to a substance, expressed on a
body weight basis, that can occur in a period of 24 hours or less
without adverse effects or harm to the user. The route of
exposure for which an ARfD applies should be specified.
Application phase The preparation (i.e. opening or accessing the product, mixing
and/or diluting of concentrates, loading application apparatus) and
administration of the (prepared) veterinary medicinal product to the
animal(s), including application by hand or any other dosing
equipment. This phase can lead to exposure of the person
administrating the product, as well as of other people who are
present during the product administration.
Benchmark Dose The Benchmark Dose (BMD) is a dose level, estimated from the
fitted dose-response curve, associated with a specified change in
response relative to the control group.
Exposure Contact with a substance by oral, dermal, parenteral, ocular and/or
inhalation routes. Exposure in the context of this guideline may be
short-term (once or for a short time), or long-term (repeated
exposure for a longer period).
Exposure assessment The process that involves estimating the magnitude, frequency, and
duration of exposure to a VMP for a specific substance, route of
exposure and user.
Exposure route The way an agent enters a human or animal after contact (e.g. by
ingestion, inhalation, or dermal absorption).
Exposure scenario A set of conditions that describe how users may accidentally come
into contact with a veterinary medicinal product during each
task/situation associated with its administration to target animals
when the VMP is used as intended and/or when handling the treated
animal.
Foreseeable accidents The use of veterinary medicinal products that is not in line with the
instructions for use or without the consideration of some or all
common and specific technical, operational and personal protective
measures (e.g. the over-dosing or inadequate dilution of a
veterinary medicinal product, common spillage scenarios, use
without or with non-proper PPE).
Hazard A biological, chemical or physical agent or situation having the
potential to cause an adverse effect.
Hazard identification The identification of biological, chemical, and physical agents or
situations capable of causing adverse effects.
Guideline on user safety for pharmaceutical veterinary medicinal products
EMEA/CVMP/543/03-Rev.2 Page 17/26
第 18 页
Hazard characterisation The qualitative and/or quantitative evaluation of the type and
nature of the inherent property of biological, chemical or physical
agents or situations having the potential to cause adverse effects. A
dose-response assessment should be performed if possible.
Lowest-observed(adverse) The lowest administered dose in a study at which (adverse)
effect-level (LO(A)EL) effect(s) are observed.
Margin of exposure (MOE) The ratio of the TRV to an estimated exposure level.
Non-respirable and respirable The non-respirable fraction of a substance refers to its airborne
fractions particles that are too large to penetrate deeply into the lungs.
These particles are typically trapped in the upper respiratory tract,
such as the nose, throat, and trachea, and do not reach the gas-
exchange regions of the lungs. These inhalable particles can be up
to 100 micrometers (µm) in diameter.
In contrast, the respirable fraction refers to the portion of airborne
particles small enough to penetrate deep into the lungs, reaching
the alveolar region where gas exchange occurs. These particles are
smaller, typically less than 10 micrometers (µm) in diameter.
No-observed-(adverse-) The highest administered dose in a study at which no (adverse)
effect-level (NO(A)EL) effect is observed.
Personal protective equipment PPE refers to specialized clothing or equipment to be worn by
(PPE) individuals to protect themselves from a health risk. Types of PPE
include: eye protection (protective glasses), respiratory protection
(masks), hand protection (gloves), body protection (protective
clothing), foot protection (safety boots).
Risk The probability of an adverse effect and the severity of that effect,
consequential to (a) hazard(s).
Risk analysis A process consisting of three components: risk assessment, risk
management and risk communication. These steps follow each
other.
Risk assessment A process intended to calculate or estimate the risk to target
animals, users, consumers of animal derived food and to the
environment, including attendant uncertainties, following exposure
to a particular agent.
Risk assessment is a science-based process consisting of the
following four steps:
(i) Hazard identification
(ii) Hazard characterisation,
(iii) Exposure assessment,
(iv) Risk characterisation.
Risk characterisation The qualitative and/or quantitative estimation, including associated
uncertainties, of the probability of occurrence and severity of known
or potential adverse effects in target animals, users, consumers of
Guideline on user safety for pharmaceutical veterinary medicinal products
EMEA/CVMP/543/03-Rev.2 Page 18/26
第 19 页
animal derived food or on the environment based on hazard
identification, hazard characterisation and exposure assessment.
Risk communication The process of communicating information about risks identified
during a risk assessment. It aims to inform and educate people
about potential hazards, their impacts, and the measures that can
be taken to mitigate the risk.
Risk management The process of evaluating risk control options and, where
necessary, implementing risk mitigation measures to reduce an
identified risk to an acceptable level for the user.
Toxicological reference value A toxicological index that, when compared to exposure, is used to
(TRV) quantify a risk for human health. TRVs are established for a given
critical effect and are specific to a substance, duration of exposure
and route of exposure (e.g. NOEL, NOAEL, BMDL).
Uncertainty factor A numerical factor applied to a toxicological (pharmacological
/microbiological) endpoint to allow for uncertainties in risk
assessment such as intraspecies (extrapolating animal data to
humans) and interindividual (variation in sensitivity among
humans) variations, the quality of the data, the severity of the
response. The factor may be a default value used in the absence of
specific information on a substance or may be modified in the light
of specific information.
User Any person that may come into contact with the veterinary
medicinal product (VMP) or components of the product before its
application to the animal (e.g. during storage), during its
application (e.g. during preparation or administration to the
animal), and after its application (e.g. through contact with the
treated animals).
588
Guideline on user safety for pharmaceutical veterinary medicinal products
EMEA/CVMP/543/03-Rev.2 Page 19/26
第 20 页
589 References
590 • Guideline on dossier requirements for anticancer medicinal products for dogs and cats
591 (EMA/CVMP/28510/2008).
592 • Guideline on user safety of topically administered veterinary medicinal products
593 (EMA/CVMP/SWP/721059/2014).
594 • Guideline on user safety for immunological veterinary medicinal products
595 (EMA/CVMP/IWP/54533/2006 Rev.1).
596 • Guideline on pharmaceutical fixed combination products (EMEA/CVMP/83804/2005).
597 • IPCS/WHO (2005). Chemical-specific adjustment factors for interspecies differences and human
598 variability: Guidance document for use of data in dose/concentration-response assessment. IPCS
599 harmonization project document no. 2. World Health Organization, Geneva, Switzerland.
600 https://www.who.int/publications/i/item/9241546786
601 • Regulation (EU) 2019/6 of the European Parliament and of the Council of 11 December 2018 on
602 veterinary medicinal products and repealing Directive 2001/82/EC.
603 • Reflection paper on providing an overview of the current regulatory testing requirements for
604 veterinary medicinal products and opportunities for implementation of the 3Rs,
605 (EMA/CHMP/CVMP/3Rs/164002/2016).
606 • VICH GL32: Studies to evaluate the safety of residues of veterinary drugs in human food:
607 Developmental toxicity testing (CVMP/VICH/485/02).
608 Abbreviations
609 ADI Acceptable Daily Intake
610 AOEL Acceptable Occupational Exposure Limit
611 ARfD Acute Reference Dose
612 BMD(L) Benchmark Dose (lower confidence limit)
613 EU European Union
614 IPCS International Program on Chemical Safety
615 LOAEL Lowest Observed Adverse Effect Level
616 MA Marketing Authorisation
617 MOE Margin of Exposure
618 NOAEL No Observed Adverse Effect Level
619 OECD Organisation for Economic Co-operation and Development
620 PPE Personal Protective Equipment
621 SPC Summary of Product Characteristics
622 TRV Toxicological Reference Value
623 VMP Veterinary Medicinal Product
Guideline on user safety for pharmaceutical veterinary medicinal products
EMEA/CVMP/543/03-Rev.2 Page 20/26
第 21 页
624 WHO World Health Organisation
625 Annex 1
626 Worked examples
627 Two worked examples of User Risk Assessments (URAs) are presented below to show a qualitative risk
628 characterisation and a quantitative risk characterisation.
629 The examples are provided to assist in understanding how URAs are conducted and do not aim to
630 provide comprehensive URAs addressing all aspects of these assessments. The two examples below
631 are for guidance purposes only and should not be regarded as exhaustive. Other concerns (e.g.
632 systemic toxicity) may need to be addressed, depending on the routes of exposure and the toxicity
633 profiles.
634 The examples are presented using the template (given in Annex 2). All URAs should include the four
635 aspects of risk assessment, namely hazard identification, hazard characterisation, exposure
636 assessment and risk characterisation, as given in this guideline and as presented in the template. It
637 may be noted that hazard identification and hazard characterisation are considered together in this
638 guideline as they are intrinsically linked.
639 Example 1: URA based on a qualitative risk characterisation
640 Brief description of product: An anthelmintic for oral administration which is provided as a suspension
641 for use in drinking water for pigs. The package size is a 4-liter plastic container, and a separate
642 dispenser (measuring device) is provided.
643 Note: Only the qualitative risk characterisation is described in this example. Adverse effects which
644 require quantitative risk assessment are not considered.
645 User Risk Assessment
646 1. Hazard Identification and Characterisation
647 Appraisal of the toxicity and hazards.
648 Pharmacology and toxicology studies, including studies on irritation and sensitisation, are presented in
649 section 3A2-3A4, though a summary with conclusions should be provided in section 3A5 URA.
650 1.1 Toxicity data on active substance(s):
651 The following was concluded for the active substance in regard to local toxicity:
652 • No skin or eye irritation studies are available for the active substance.
653 • Observations in humans indicate skin irritation following dermal contact with the active substance.
654 1.2 Toxicity data on formulation:
655 The following was concluded for the formulation in regard to local toxicity:
656 • A skin irritation study with the final formulation showed mild irritation.
657 • An eye irritation study showed no signs of irritation.
658 • A skin sensitisation study showed no evidence of sensitisation.
Guideline on user safety for pharmaceutical veterinary medicinal products
EMEA/CVMP/543/03-Rev.2 Page 21/26
第 22 页
659 2. Exposure
660 Appraisal of the exposure.
661 2.1 Precise identification of the product
662 • The product is a suspension presented in a 4-litre plastic container. A separate dispenser is
663 provided for dosing.
664 • The VMP is to be administered via drinking water to pigs.
665 2.2 Exposure scenarios
666 • Exposure may occur during the application phase (when added to the drinking water and
667 administered to the animals) or the post-application phase (during cleaning of the dispenser and
668 disposal activities).
669 2.3 Type of user
670 • The VMP will be applied by farmers. Children are not expected to have access to the VMP as this
671 VMP is to be used by professional users and kept in a professional environment.
672 2.4 Routes of exposure
673 • The main routes of exposure are dermal exposure from accidental spillage when handling the
674 product and when cleaning the dispenser after dosing. Exposure of the eyes may also be possible
675 through splashes when adding the VMP to the drinking water.
676 2.5 Magnitude, duration and frequency of exposure
677 • Under normal conditions of use, skin and eye exposure is possible every time the VMP is
678 administered, i.e. when added to the drinking water due to accidental spillage and/or splashes.
679 Skin exposure is very likely when cleaning the dispenser.
680 Note that, as only the qualitative risk assessment is described in this example, no exposure level is
681 estimated.
682 3. Risk characterisation
683 3.1 Qualitative risk characterisation
684 • The risks following eye exposure are considered negligible, because adverse effects to the eyes are
685 not expected in view of the negative eye irritation study with the formulation.
686 • A skin irritation study with the final formulation showed a mild irritating effect. Irritation of the skin
687 in humans was observed after dermal contact with the active substance.
688 • The risk for skin sensitisation is low in view of the negative skin sensitisation study.
689 3.2 Quantitative risk characterisation
690 Quantitative risk not determined in this example.
691 4 Risk Management.
692 • Risk mitigation measures should be in place to address the possibility of irritation after accidental
693 skin exposure when preparing the medicated drinking water and cleaning the dispenser.
Guideline on user safety for pharmaceutical veterinary medicinal products
EMEA/CVMP/543/03-Rev.2 Page 22/26
第 23 页
694 5 Risk Communication.
695 The user warnings on the SPC and package leaflet are 5:
696 • This veterinary medicinal product may be irritating to the skin. (A)
697 • Avoid skin contact. (B)
698 • Personal protective equipment consisting of impervious gloves should be worn when handling the
699 veterinary medicinal product and cleaning the measuring device. (C)
700 • Wash hands after use. (D)
701 • In case of accidental spillage onto the skin, immediately rinse with plenty of water. Remove
702 contaminated clothing after spillage. If irritation persists, seek medical advice and show the label or
703 package leaflet to the physician. (D)
704 Example 2: URA based on a quantitative risk characterisation
705 Brief description of product: A VMP for oral administration to dogs by a pet owner at home. There are
706 two strengths of coated tablets, 20 mg and 50 mg.
707 Only the quantitative risk characterisation is described in this example.
708 User Risk Assessment
709 1. Hazard Identification and Characterisation
710 Appraisal of the toxicity and hazards.
711 Pharmacology and toxicology studies are presented in section 3A2-3A4, though a summary with
712 conclusions on the relevant (lowest) TRVs should be provided in section 3A5 URA.
713 1.1 Toxicity data on active substance(s).
714 The following was concluded for the active substance:
715 • NOAEL = 10 mg/kg, based on a 14-day toxicity study in dogs, where dizziness and low blood
716 pressure were observed at higher doses.
717 1.2 Toxicity data on formulation.
718 No toxicity studies using the formulation are presented. The systemic toxicity is determined by the
719 active substance.
720 2. Exposure
721 Appraisal of the exposure.
722 2.1 Precise identification of the product
723 • The VMP is presented in cartons containing 10 blister strips, each strip containing 10 coated tablets
724 of 20 mg or 50 mg.
725 • Tablets are administered to the animals once or twice a day.
5 The capital letters in brackets correspond to those used in section 5.5. of this guideline
Guideline on user safety for pharmaceutical veterinary medicinal products
EMEA/CVMP/543/03-Rev.2 Page 23/26
第 24 页
726 2.2 Exposure scenarios.
727 • Exposure may occur during the pre-administration phase (storage, as the VMP is stored at home)
728 and during the administration phase (when administered to the animal).
729 2.3 Type of user
730 • The VMP will be administered by dog owners. Children may get access to the VMP if not properly
731 stored.
732 2.4 Routes of exposure
733 • The main routes of exposure are dermal exposure from handling the tablets or accidental ingestion
734 of the tablets by a child.
735 2.5 Magnitude, duration and frequency of exposure
736 • When handling the tablet, skin exposure is estimated to be negligible in view of the coating on the
737 tablet. Accidental ingestion by a child in the home needs to be addressed. A young child of
738 approximately 12.5 kg body weight (bw) ingesting 1 tablet is considered to be a reasonable worst-
739 case scenario, as it is assumed that a young child may be left unattended for a short time and the
740 VMP is packed in a blister.
741 • Accidental ingestion of one 50 mg tablet in a single exposure would give a dose of 50 mg or 4
742 mg/kg bw when considering the bw of 12.5 kg.
743 3. Risk characterisation
744 3.1 Qualitative risk characterisation
745 - Qualitative risk is not determined in this example.
746 3.2 Quantitative risk characterisation
747 Based on the exposure of 4 mg/kg bw as a result of the ingestion of one 50 mg tablet by a 12.5 kg
748 child, and considering the NOAEL of 10 mg/kg, the MOE is 10/4= 2.5. This MOE is lower than 100 (the
749 factor needed to take account of intra- and interspecies variation), it is therefore considered that risk
750 mitigation measures should be in place.
751 4 Risk Management
752 • Because of the risk of accidental ingestion, risk mitigation measures should be in place to prevent
753 children from accidentally ingesting tablets.
754 5 Risk Communication
755 The user warnings on the SPC and package leaflet are:
756
757 • This veterinary medicinal product may cause dizziness or low blood pressure. (A)
758 • Avoid accidental ingestion. (B)
759 • Care should be taken to prevent accidental ingestion by children. In order to prevent children from
760 accessing the product, do not remove tablets from the blister until ready to administer to the
Guideline on user safety for pharmaceutical veterinary medicinal products
EMEA/CVMP/543/03-Rev.2 Page 24/26
第 25 页
761 animal. Tablets should be administered and stored (in the original packaging) out of the sight and
762 reach of children. (C)
763 • In case of accidental ingestion, seek medical advice immediately and show the package leaflet or
764 the label to the physician. (D)
765
Guideline on user safety for pharmaceutical veterinary medicinal products
EMEA/CVMP/543/03-Rev.2 Page 25/26
第 26 页
766 Annex 2
767 Template for a user risk assessment
768 The following template can be used to present a user risk assessment, however it should be noted that
769 all the headings may not be needed and can be deleted as required.
770 User Risk Assessment
771 1. Hazard Identification and Characterisation
772 1.1 Toxicity data on active substance(s)
773 1.2 Toxicity data on formulation
774 2. Exposure assessment
775 2.1 Precise identification of the product
776 2.2 Exposure scenarios
777 2.3 Type of user
778 2.4 Routes of exposure
779 2.5 Components of a product to which the user is exposed
780 2.6 Magnitude, duration and frequency of exposure
781 3. Risk characterisation
782 3.1 Qualitative risk characterisation
783 3.2 Quantitative risk characterisation
784 4 Risk Management
785 5 Risk Communication
Guideline on user safety for pharmaceutical veterinary medicinal products
EMEA/CVMP/543/03-Rev.2 Page 26/26
来源:EMA 官方医药监管信息 · ema.europa.eu